CD8A and neoplasm: A consistent hallmark of OV therapy, particularly when combined with checkpoint inhibitors, is the increased infiltration of CD8+ cytotoxic T cells, along with elevated PD-L1 expression and IFN-γ gene expression in the tumor microenvironment.